Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches-Reference-Cited by-同舟云学术

Structural Basis of Activin Receptor-Like Kinase 2 (R206H) Inhibition by Bis-heteroaryl Pyrazole-Based Inhibitors for the Treatment of Fibrodysplasia Ossificans Progressiva Identified by the Integration of Ligand-Based and Structure-Based Drug Design Approaches

Published:2020-05-12 Issue:20 Volume:5 Page:11411-11423
ISSN:2470-1343
Container-title:ACS Omega
language:en
Short-container-title:ACS Omega

Author:

Sato Tomohiro¹^ORCID,Sekimata Katsuhiko²,Sakai Naoki³,Watanabe Hisami³,Mishima-Tsumagari Chiemi³,Taguri Tomonori²,Matsumoto Takehisa³,Fujii Yoshifumi⁴,Handa Noriko⁴,Tanaka Akiko³,Shirouzu Mikako³,Yokoyama Shigeyuki⁴^ORCID,Hashizume Yoshinobu⁵,Miyazono Kohei⁶,Koyama Hiroo²,Honma Teruki¹^ORCID

Affiliation:

1. Drug Discovery Computational Chemistry Platform Unit, RIKEN Center for Biosystems Dynamics Research, 1−7−22 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan

2. Drug Discovery Chemistry Platform Unit, RIKEN Center for Sustainable Resource Science, 2−1 Hirosawa, Wako, Saitama 351-0198, Japan

3. Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research, 1−7−22 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan

4. Crystallographic Drug Discovery Platform Unit, RIKEN Systems and Structural Biology Center, 1−7−22 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan

5. RIKEN Program for Drug Discovery and Medical Technology Platforms, 2−1 Hirosawa, Wako, Saitama 351-0198, Japan

6. Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, 7−3−1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

Funder

Ministry of Education, Culture, Sports, Science and Technology

Japan Agency for Medical Research and Development

Publisher

American Chemical Society (ACS)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.acs.org/doi/pdf/10.1021/acsomega.9b04245

Reference42 articles.

1. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva

2. ALK2 R206H Mutation Linked to Fibrodysplasia Ossificans Progressiva Confers Constitutive Activity to the BMP Type I Receptor and Sensitizes Mesenchymal Cells to BMP-Induced Osteoblast Differentiation and Bone Formation

3. Structure of the Bone Morphogenetic Protein Receptor ALK2 and Implications for Fibrodysplasia Ossificans Progressiva

4. Applications of small molecule BMP inhibitors in physiology and disease

5. A Survey of Strategies to Modulate the Bone Morphogenetic Protein Signaling Pathway: Current and Future Perspectives

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects;European Journal of Medicinal Chemistry;2024-10

2. Activin receptor-like kinase-2 inhibitors;Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy;2024

3. Designing drugs when there is low data availability: one-shot learning and other approaches to face the issues of a long-term concern;Expert Opinion on Drug Discovery;2022-08-30

4. Multi-omics therapeutic perspective on ACVR1 gene: from genetic alterations to potential targeting;Briefings in Functional Genomics;2022-08-25

5. Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years;Frontiers in Cell and Developmental Biology;2022-05-25